The question is... what will we rerate to, and what partnerships have now moved from middleground to foreground.
According to our timeline, after FDA ODD (and this bonus RPDD and likely Fast Track) we are now into the partnership stage.
With our 1102 trial to start first quarter next year, what partnership is coming up? So far so good regarding the checklist path forward as projected some months back by ANP.
Ann: Trading Halt, page-29
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $117.2M | |||
| Open | High | Low | Value | Volume |
| 13.5¢ | 14.0¢ | 13.0¢ | $168.5K | 1.260M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 633259 | 13.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.5¢ | 874939 | 7 |
View Market Depth
| Last trade - 16.10pm 14/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |